Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accumulated Expenses (2023 - 2025)

Kura Oncology (KURA) has disclosed Accumulated Expenses for 3 consecutive years, with $10.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $10.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $10.0 million, a N/A change, with the full-year FY2024 number at $17.5 million, up 33.11% from a year prior.
  • Accumulated Expenses was $10.0 million for Q2 2025 at Kura Oncology, down from $17.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $17.5 million in Q4 2024 to a low of $6.1 million in Q1 2024.
  • A 3-year average of $11.7 million and a median of $11.6 million in 2023 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 33.11% in 2024; the steepest drop was 33.11% in 2024.
  • Kura Oncology's Accumulated Expenses stood at $13.2 million in 2023, then surged by 33.11% to $17.5 million in 2024, then crashed by 42.72% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Accumulated Expenses are $10.0 million (Q2 2025), $17.5 million (Q4 2024), and $6.1 million (Q1 2024).